₨ 45,000
Prolia 60 mg/ml solution for injection (denosumab) is a prescription medication used primarily to treat osteoporosis and reduce fracture risk in certain high-risk individuals. It functions as a monoclonal antibody that inhibits bone breakdown.
Key Information
- Active Ingredient: Denosumab.
- Manufacturer: Amgen.
- Purpose:
- Treatment of osteoporosis in postmenopausal women and men at increased risk of fractures.
- Treatment of bone loss in men and women receiving certain cancer treatments (e.g., for prostate or breast cancer) that can weaken bones.
- Treatment of bone loss in patients receiving long-term steroid therapy.
- Administration: A healthcare provider administers the medication as a single subcutaneous (under the skin) injection once every six months into the upper arm, thigh, or abdomen.
- Mechanism: Denosumab works by blocking a protein called RANK ligand (RANKL), which is involved in the formation and activity of cells that break down bone (osteoclasts). This action helps to make bones stronger and less likely to break.
- Important Considerations:
- Patients should receive adequate calcium and vitamin D supplementation as directed by a doctor.
- It is crucial not to stop or delay doses without consulting a healthcare provider, as this can increase the risk of multiple spinal fractures.
- Patients with advanced kidney disease are at risk of severely low calcium levels.
- Rare side effects include osteonecrosis of the jaw (jaw bone problems) and unusual thigh bone fractures, so good oral hygiene is essential.
Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for any questions regarding a medical condition or treatment.
₨ 10,000
